Minor adverse events · people with active UC
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · People with quiescent Crohn's disease (ileocolic resection)
It is very uncertain whether adalimumab changes failure to maintain endoscopic remission compared with active comparator (very low certainty).
1 finding from 1 review
Anxiety · people with inflammatory bowel disease
2 findings from 1 review
Depression at 12 weeks · people with inflammatory bowel disease
1 finding from 1 review
Depression at 12 months · people with inflammatory bowel disease
1 finding from 1 review
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Pain · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of remission · people with inflammatory bowel disease
Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).
1 finding from 1 review
Endoscopic relapse · people with inflammatory bowel disease
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with active Crohn's disease
Antibiotic leads to lower failure to enter clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to achieve clinical response or remission · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in failure to achieve clinical response or remission compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found